Project Grant R01CA314254
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $524K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant totaling $683,075 under the Cancer Cause and Prevention Research program (CFDA 93.393) on March 24, 2026. This five-year research project, scheduled for completion on February 28, 2031, investigates the mitotic function of 53BP1 and its negative regulator TIRR (TIRR/53BP1 Complex Regulates Mitotic Fidelity and Immune-Mediated Radiation Response). The research examines how...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $323,860 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) on August 18, 2025, with completion targeted for April 30, 2028. This award supports research investigating the role of mutagenic DNA repair pathways in cancer cell persistence and acquired drug resistance. The project focuses on understanding how cancer cells under stress from anti-cancer...
- Federal Grant Award Summary The National Cancer Institute awarded a $211,112 Project Grant to Harvard Medical School (President and Fellows of Harvard College) on August 14, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award supports basic cancer research investigating the role of Replication Protein A (RPA) in polymerase theta-mediated end-joining (TMEJ), a mutagenic DNA double-strand break (DSB) repair pathway that cancer cells dependent on deficient homologous...
- Federal Project Grant Summary Beth Israel Deaconess Medical Center, Inc. received a $818,625 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. The award funds a randomized controlled trial evaluating cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with pre-existing cardiomyopathy or prior anthracycline exposure. The primary...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput technological tools for tracking the fate of prematurely terminated transcripts in cancer cells. The project, which extends through February 28, 2029, focuses on advancing understanding of alternative polyadenylation (APA) events—RNA processing mechanisms that drive oncogenesis independent of DNA...
- Federal Grant Award Summary The National Cancer Institute awarded a $430,521 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Beth Israel Deaconess Medical Center, effective March 13, 2026, with a completion date of February 28, 2029. The project deliverables focus on developing novel monoclonal antibody tools to investigate altered glycosylation patterns in tumor cells. The research involves creating tumor-associated carbohydrate antigen (TACA)-specific monoclonal...
- Federal Grant Award Summary The National Cancer Institute awarded $125,619 to the Stowers Institute for Medical Research under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This Project Grant supports research into centromere biology and chromosome segregation mechanisms that contribute to genomic instability—a hallmark of cancer development. The primary deliverables include experimental research characterizing how natural...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., a Project Grant of $734,942 under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This project addresses cardiovascular disease (CVD) risk in breast cancer survivors by generating novel DNA methylation biomarker data from the Pathways Study, a prospective cohort of 4,504 women diagnosed with...